Aldeyra Therapeutics, Inc. ALDX
Analyst Ratings
- Consensus
- Moderate Buy — 1 Buy · 1 Hold · 0 Sell (2 analysts)
- Avg. Price Target
- $5.50 (+506.0% upside)
Key Stats
- Today's Range
- $0.88 – $0.92
- 50-Day Range
- $0.86 – $1.67
- 52-Week Range
- $0.86 – $5.93
- Volume
- 74K shs
- Average Volume
- 1.36 million shs
- Market Cap
- $55.25 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.45%
- Days to Cover
- 3.99
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Related Stocks
Compare head-to-head: ALDX vs LLY·ALDX vs JNJ·ALDX vs ABBV·ALDX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.